
X世代出生于上世纪60年代末至80年代,夹在掌握主流话语权的婴儿潮一代与千禧一代中间,常被称作“被遗忘的一代”,在网上关于肉毒素的讨论中鲜有存在感。
但如今,X世代走进整形外科诊所,诉求早已不止除皱,更包括接受面部拉皮手术——这类手术过去的受众通常比他们年长15岁。背后推手正是GLP-1减肥药:这类药物会造成脸颊凹陷、下颌皮肤松弛,并加速面部衰老,而这些问题仅靠肉毒素是无法修复的。
美国整形外科医师学会(American Society of Plastic Surgeons)主席鲍勃·巴苏(Bob Basu)博士指出,那些曾在MTV上观看迈克尔·杰克逊和麦当娜表演的年轻人,如今已步入中年,正感受到“四五十岁时出现的自然衰老迹象”。
“无论男女,都想重回自己状态最佳时的样貌,我认为这推动了微创医美项目的需求增长。”巴苏在接受《财富》杂志采访时表示。
X世代不再局限于填充剂和肉毒素,开始尝试以往仅面向更年长人群的手术项目。这一趋势既源于人们对面部衰老的关注,也源于GLP-1类药物的普及。
“25年前,面部拉皮手术的受众基本都是60岁以上人群。现在情况完全不同了,”巴苏告诉《财富》杂志,“我们看到越来越多四五十岁的患者选择面部年轻化手术。”
巴苏解释道,GLP-1类药物往往会导致脸颊、下颌和颈部的软组织流失与皮肤松弛,因此X世代群体产生了手术需求——按常规标准来看,他们进行这些手术时年龄普遍偏低。
美国面部整形与重建外科学会(American Academy of Facial Plastic and Reconstructive Surgery)的数据显示,2024年脂肪移植手术量增长了50%,外科医生将这一激增直接归因于“司美格鲁肽脸”——即服用GLP-1药物快速减重后出现的脸颊凹陷与皮肤松弛问题。目前有四分之一的面部整形医生预计,GLP-1类药物将持续拉动手术类与非手术类医美项目需求。
美国皮肤外科学会(American Society for Dermatologic Surgery )2025年对3500多名消费者开展的调查显示,年长千禧一代与X世代受访者渴望外在容貌贴合自身的年轻心态,或是看上去比真实年龄更小,他们非常担心眼周和面中部的细纹和皱纹。
外科医生还提到了持续的“Zoom效应”——疫情期间,X世代常年在视频通话中盯着自己的脸,敏锐地察觉到自身面部衰老,这是前几代人从未经历过的。
梅雷迪思·芬恩(Meredith Finn)是一名带薪休假专家,也是X世代的一员。她最初从母亲乡村俱乐部的朋友那里听说肉毒素,此后每年接受数次注射。
芬恩告诉《财富》杂志:“我只是开始觉得眼周的细纹变多,就想找我母亲提过的那位口碑不错的医生咨询一下。”
填充剂、肉毒素与整形手术的成本对比
芬恩表示,如果经济条件允许,她会更频繁地接受注射治疗。肉毒素治疗的平均费用为420美元,初期费用远低于手术,但由于这种神经调节剂的效果会逐渐消退,需每隔数月注射一次,才能维持效果。
相比之下,手术效果是永久性的,从长远来看,可能更划算、更有效。这或许能解释,为何近五分之二的整形手术受众是X世代——尽管选择微创项目的人数是手术的两倍。
尽管如此,X世代对注射类项目的需求依然惊人:根据美国整形外科医师学会的最新数据,2024年,40至54岁人群接受了近1100万次微创手术,占当年所有神经调节剂注射(包括肉毒素、吉适、达希斐及类似项目)总量的一半以上,超过千禧一代、Z世代与部分婴儿潮一代的总和。
巴苏表示:“现实情况是,微创项目可能并非实现他们目标的最佳选择,多数情况下,手术才是最优解决方案。”
目前,X世代是抗衰美妆产品的消费主力,且越来越有能力承担单次费用高达数千美元的整形手术。预计未来十年,X世代的购买力将达到23万亿美元,成为全球消费能力最强的世代。(财富中文网)
译者:中慧言-王芳
X世代出生于上世纪60年代末至80年代,夹在掌握主流话语权的婴儿潮一代与千禧一代中间,常被称作“被遗忘的一代”,在网上关于肉毒素的讨论中鲜有存在感。
但如今,X世代走进整形外科诊所,诉求早已不止除皱,更包括接受面部拉皮手术——这类手术过去的受众通常比他们年长15岁。背后推手正是GLP-1减肥药:这类药物会造成脸颊凹陷、下颌皮肤松弛,并加速面部衰老,而这些问题仅靠肉毒素是无法修复的。
美国整形外科医师学会(American Society of Plastic Surgeons)主席鲍勃·巴苏(Bob Basu)博士指出,那些曾在MTV上观看迈克尔·杰克逊和麦当娜表演的年轻人,如今已步入中年,正感受到“四五十岁时出现的自然衰老迹象”。
“无论男女,都想重回自己状态最佳时的样貌,我认为这推动了微创医美项目的需求增长。”巴苏在接受《财富》杂志采访时表示。
X世代不再局限于填充剂和肉毒素,开始尝试以往仅面向更年长人群的手术项目。这一趋势既源于人们对面部衰老的关注,也源于GLP-1类药物的普及。
“25年前,面部拉皮手术的受众基本都是60岁以上人群。现在情况完全不同了,”巴苏告诉《财富》杂志,“我们看到越来越多四五十岁的患者选择面部年轻化手术。”
巴苏解释道,GLP-1类药物往往会导致脸颊、下颌和颈部的软组织流失与皮肤松弛,因此X世代群体产生了手术需求——按常规标准来看,他们进行这些手术时年龄普遍偏低。
美国面部整形与重建外科学会(American Academy of Facial Plastic and Reconstructive Surgery)的数据显示,2024年脂肪移植手术量增长了50%,外科医生将这一激增直接归因于“司美格鲁肽脸”——即服用GLP-1药物快速减重后出现的脸颊凹陷与皮肤松弛问题。目前有四分之一的面部整形医生预计,GLP-1类药物将持续拉动手术类与非手术类医美项目需求。
美国皮肤外科学会(American Society for Dermatologic Surgery )2025年对3500多名消费者开展的调查显示,年长千禧一代与X世代受访者渴望外在容貌贴合自身的年轻心态,或是看上去比真实年龄更小,他们非常担心眼周和面中部的细纹和皱纹。
外科医生还提到了持续的“Zoom效应”——疫情期间,X世代常年在视频通话中盯着自己的脸,敏锐地察觉到自身面部衰老,这是前几代人从未经历过的。
梅雷迪思·芬恩(Meredith Finn)是一名带薪休假专家,也是X世代的一员。她最初从母亲乡村俱乐部的朋友那里听说肉毒素,此后每年接受数次注射。
芬恩告诉《财富》杂志:“我只是开始觉得眼周的细纹变多,就想找我母亲提过的那位口碑不错的医生咨询一下。”
填充剂、肉毒素与整形手术的成本对比
芬恩表示,如果经济条件允许,她会更频繁地接受注射治疗。肉毒素治疗的平均费用为420美元,初期费用远低于手术,但由于这种神经调节剂的效果会逐渐消退,需每隔数月注射一次,才能维持效果。
相比之下,手术效果是永久性的,从长远来看,可能更划算、更有效。这或许能解释,为何近五分之二的整形手术受众是X世代——尽管选择微创项目的人数是手术的两倍。
尽管如此,X世代对注射类项目的需求依然惊人:根据美国整形外科医师学会的最新数据,2024年,40至54岁人群接受了近1100万次微创手术,占当年所有神经调节剂注射(包括肉毒素、吉适、达希斐及类似项目)总量的一半以上,超过千禧一代、Z世代与部分婴儿潮一代的总和。
巴苏表示:“现实情况是,微创项目可能并非实现他们目标的最佳选择,多数情况下,手术才是最优解决方案。”
目前,X世代是抗衰美妆产品的消费主力,且越来越有能力承担单次费用高达数千美元的整形手术。预计未来十年,X世代的购买力将达到23万亿美元,成为全球消费能力最强的世代。(财富中文网)
译者:中慧言-王芳
As the “forgotten generation” squashed between the culturally dominant Boomers and millennials, the people born between the late 60s and 80s often go under the radar in conversations about Botox online.
But that generation is now arriving at plastic surgeons’ offices not just for wrinkle treatments, but for facelifts once reserved for patients 15 years their senior, driven by a wave of GLP-1 weight-loss drugs that are hollowing cheeks, sagging jowls, and accelerating facial aging in ways Botox simply can’t fix.
The youngsters who watched Michael Jackson and Madonna on MTV are now middle-aged adults who are feeling the “natural signs of aging that occur in your 40s and 50s,” according to Dr. Bob Basu, the president of the American Society of Plastic Surgeons.
“Men and women want to restore the best version of themselves, and I think that helps to drive demand for minimally invasive procedures,” Basu told Fortune.
Gen X is also going beyond fillers and Botox and into surgeries once reserved for more elderly patients, a trend that’s driven by both awareness of facial aging and GLP-1s.
“You know, 25 years ago, the people who would get face lifts are basically a 60-plus crowd. That’s not the case anymore,” Basu told Fortune. “We’re seeing more and more patients in their 40s and 50s that are opting for facial rejuvenation.”
Basu explained that GLP-1s can often lead to loss of volume and sagging in people’s cheeks, jowls and necks, hence the demand for surgery in the Gen X group that would otherwise be fairly young for those procedures.
The American Academy of Facial Plastic and Reconstructive Surgery reported a 50% rise in fat-grafting procedures in 2024, with surgeons directly attributing the spike to “Ozempic face” — the hollowed cheeks and sagging skin that follow rapid GLP-1-driven weight loss. One in four facial plastic surgeons now anticipates GLP-1s will continue driving demand for both surgical and nonsurgical treatments.
A 2025 American Society for Dermatologic Surgery survey of more than 3,500 consumers found that the respondents in the elder millennial and Gen X range wanted to look as young as they feel or better for their age, and are worried about lines and wrinkles around the eyes and mid-face.
Surgeons also point to a lasting “Zoom boom” effect — Gen Xers who have now spent years staring at their own faces on video calls during the pandemic and become acutely aware of their facial aging in a way prior generations never experienced.
Meredith Finn, a paid leave specialist and Gen Xer, first started getting Botox after hearing about it from her mom’s country club friends, and has been getting injections a few times a year ever since.
“I just started to feel like I was seeing more lines around my eyes or something, and thought I would just go check out this doctor my mother had heard was good,” Finn told Fortune.
The economics of fillers and Botox compared to plastic surgeries
Finn said she would get injectables more often if she could afford it. Botox treatment costs $420 on average, much cheaper initially than surgery, but it requires injections every few months to maintain the results, since the neuromodulator wears off.
With surgery, on the other hand, the results are permanent, which could be cheaper and more effective in the long run. This may explain why nearly two in five of all surgical procedures were done by Gen X, though double the number of people opted for minimally invasive procedures.
Still, the sheer scale of Gen X’s appetite for injectables is striking: people between 40 and 54 underwent close to 11 million minimally invasive procedures in 2024, accounting for more than half of all neuromodulator injections — Botox, Dysport, Daxxify and similar treatments — that year, more than millennials, Gen Z, and a slice of Boomers combined, according to the latest data from the American Society of Plastic Surgeons.
“The reality is minimally invasive may not be the best option to achieve their goals, and so many times, surgical procedures are the best route,” Basu said.
Gen X currently drives beauty sales for products focused on anti-aging and can increasingly afford to pay for multiple thousand-dollar-a-piece cosmetic surgeries, with its buying power projected to hit $23 trillion in the next decade, the highest spending generation in the world.